Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 19 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

12 recruiting

Enrollment Performance

Analytics

Phase 4
3(42.9%)
N/A
3(42.9%)
Early Phase 1
1(14.3%)
7Total
Phase 4(3)
N/A(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT06284642Phase 4Recruiting

Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)

Role: collaborator

NCT07179159Not ApplicableRecruiting

Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

Role: collaborator

NCT07335406Recruiting

Registry for the Management of Helicobacter Pylori Infection in Shandong Province

Role: collaborator

NCT07495111Not ApplicableRecruiting

Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis

Role: collaborator

NCT07413068Recruiting

Treatment Outcomes and Complications of Three Therapeutic Approaches for Concomitant Choledocholithiasis and Cholecystolithiasis

Role: collaborator

NCT07402135Not ApplicableNot Yet Recruiting

Fecal Noninvasive Biomarkers Oriented Control Versus Usual Care Strategy in Ulcerative Colitis

Role: collaborator

NCT07379281Recruiting

Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology

Role: collaborator

NCT07379255Recruiting

Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07379268Recruiting

Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07285096Recruiting

P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Role: collaborator

NCT07167511Completed

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Role: collaborator

NCT07111273Not Yet Recruiting

DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis

Role: collaborator

NCT07111572Not Yet Recruiting

Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis

Role: collaborator

NCT06285734Recruiting

Clinical Characteristics of Small Intestinal Bacterial Overgrowth in Individuals with Abdominal Distention

Role: collaborator

NCT06723197Phase 4Recruiting

Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication

Role: collaborator

NCT06592118Completed

Clinical and Surgical Outcomes of Thyroid Carcinoma in Children and Adolescents

Role: lead

NCT06557018Phase 4Recruiting

Efficacy and Safety of Liposomal Bupivacaine Using Periarticular Injection in Total Knee Arthroplasty

Role: lead

NCT06437912Early Phase 1Completed

Effectiveness of Botulinum Toxin A in Preventing Scar Formation and Initial Exploration of "Optimal Concentration"

Role: lead

NCT06437873Completed

Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC

Role: lead

All 19 trials loaded